{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:07:03Z","timestamp":1780499223284,"version":"3.54.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":90,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["EIN202020-1123381"],"award-info":[{"award-number":["EIN202020-1123381"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["PI21\/01292"],"award-info":[{"award-number":["PI21\/01292"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["RD21\/0005\/0016"],"award-info":[{"award-number":["RD21\/0005\/0016"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["TV3 2021 215\/C\/2021"],"award-info":[{"award-number":["TV3 2021 215\/C\/2021"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP21\/00109"],"award-info":[{"award-number":["PMP21\/00109"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0005\/0001"],"award-info":[{"award-number":["RD21\/0005\/0001"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.nefroe.2023.09.002","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T09:59:27Z","timestamp":1697450367000},"page":"386-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Jose Luis","family":"G\u00f3rriz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Facila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2023.09.002_bib0005","series-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2021"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"34","author":"Jager","year":"2019","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ckj\/sfab170","article-title":"RICORS2040: the need for collaborative research in chronic kidney disease","volume":"15","author":"Ortiz","year":"2021","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/dom.14601","article-title":"Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials","volume":"24","author":"Chaudhuri","year":"2022","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0025","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.kint.2017.01.030","article-title":"Diabetes with early kidney involvement may shorten life expectancy by 16 years","volume":"92","author":"Wen","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0030","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ckj\/sfz007","article-title":"Clarifying the concept of chronic kidney disease for non-nephrologists","volume":"12","author":"Perez-Gomez","year":"2019","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0035","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/ndt\/gfx376","article-title":"Albumin downregulates Klotho in tubular cells","volume":"33","author":"Fernandez-Fernandez","year":"2018","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0040","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/HYPERTENSIONAHA.120.16635","article-title":"Role of klotho in the development of essential hypertension","volume":"77","author":"Kanbay","year":"2021","journal-title":"Hypertension."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0045","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0050","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0055","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0060","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0065","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0070","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0075","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0080","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease \u2013 mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1753944708100409","article-title":"Aldosterone and progression of kidney disease","volume":"3","author":"Cortinovis","year":"2009","journal-title":"Ther Adv Cardiovasc Dis."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0090","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.nefro.2020.10.001","article-title":"Bloqueantes del receptor mineralcorticoide en la enfermedad renal cr\u00f3nica","volume":"41","author":"Erraez","year":"2021","journal-title":"Nefrologia."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0095","unstructured":"Finerenona. Ficha t\u00e9cnica. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kerendia-epar-product-information_es.pdf."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0100","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"4S","key":"10.1016\/j.nefroe.2023.09.002_bib0105","first-page":"S1","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0110","unstructured":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Marzo 2022. Available from: https:\/\/kdigo.org\/wp-content\/uploads\/2022\/03\/KDIGO-2022-Diabetes-Management-GL_Public-Review-draft_1Mar2022.pdf."},{"issue":"Suppl 1","key":"10.1016\/j.nefroe.2023.09.002_bib0115","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.2337\/dc22-S011","article-title":"Chronic kidney disease and risk management: standards of medical care in diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000515622","article-title":"Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present","volume":"52","author":"Epstein","year":"2021","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0125","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s13300-022-01236-w","article-title":"A podcast discussing aldosterone and mineralocorticoid receptor antagonists in 2021: a paradigm shift","volume":"13","author":"Epstein","year":"2022","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0130","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0135","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0145","doi-asserted-by":"crossref","first-page":"T67","DOI":"10.1530\/JOE-17-0009","article-title":"30 years of the mineralocorticoid receptor: The role of the mineralocorticoid receptor in the vasculature","volume":"234","author":"DuPont","year":"2017","journal-title":"J Endocrinol."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease","volume":"25","author":"Alicic","year":"2018","journal-title":"Adv Chronic Kidney Dis."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0155","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41581-019-0248-y","article-title":"Targeting the progression of chronic kidney disease","volume":"16","author":"Ruiz-Ortega","year":"2020","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0160","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0165","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-022-02223-0","article-title":"A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches","author":"Mima","year":"2022","journal-title":"Adv Ther."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0175","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.754239","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"12","author":"Kawanami","year":"2021","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0190","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","article-title":"Finerenone: first approval","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0195","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0200","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2215\/CJN.13121215","article-title":"Inflammation and progression of CKD: the CRIC study","volume":"11","author":"Amdur","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0205","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MNH.0000000000000340","article-title":"Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease","volume":"26","author":"Dojki","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0210","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0215","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0220","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.21037\/apm-21-763","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis","volume":"10","author":"Fu","year":"2021","journal-title":"Ann Palliat Med."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0225","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000521908","article-title":"Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease","volume":"47","author":"Zheng","year":"2022","journal-title":"Kidney Blood Press Res."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0230","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1681\/ASN.20213210S145b","article-title":"Finerenone in patients with CKD and type 2 diabetes by SGLT-2i treatment: the fidelity analysis","volume":"32","author":"Rossing","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0235","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-Lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0240","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfac046","article-title":"SGLT2 inhibitors and finerenone: one or the other or both?","author":"Neuen","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0245","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0250","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0255","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0260","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol."},{"issue":"4","key":"10.1016\/j.nefroe.2023.09.002_bib0265","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0270","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13300-020-00798-x","article-title":"The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes","volume":"11","author":"Yin","year":"2020","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0275","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13300-021-01198-5","article-title":"Glucagon-like peptide-1 receptor agonist use in people living with type 2 diabetes mellitus and chronic kidney disease: a narrative review of the key evidence with practical considerations","volume":"13","author":"G\u00f3rriz","year":"2022","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0280","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"10.1016\/j.nefroe.2023.09.002_bib0285","first-page":"01051","article-title":"Antifibrotic agents for the management of CKD: a review","volume":"S0272-6386","author":"Ruiz-Ortega","year":"2022","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0290","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12913-021-06566-2","article-title":"Costs and healthcare utilisation of patients with chronic kidney disease in Spain","volume":"21","author":"Escobar","year":"2021","journal-title":"BMC Health Serv Res."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0295","first-page":"34","article-title":"Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal cr\u00f3nica","volume":"34","author":"G\u00f3mez-Huelgas","year":"2014","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.09.002_bib0300","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.endonu.2014.06.003","article-title":"Documento de consenso para la detecci\u00f3n y manejo de la enfermedad renal cr\u00f3nica","volume":"61","author":"Mart\u00ednez-Castelao","year":"2014","journal-title":"Endocrinol Nutr."},{"issue":"Suppl 1","key":"10.1016\/j.nefroe.2023.09.002_bib0305","doi-asserted-by":"crossref","first-page":"i13","DOI":"10.1093\/ndt\/gfz237","article-title":"Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease","volume":"35","author":"G\u00f3rriz","year":"2020","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2023.09.002_bib0310","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423001463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423001463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:39:38Z","timestamp":1762598378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251423001463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2013251423001463"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.09.002","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2022.09.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}